Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	Hierarchical composite outcome	Day 30	Hierarchical composite of Win Ratio at day 30: * death; * new extracorporeal membrane oxygenation (ECMO), * new invasive mechanical ventilation; * severe (CTCAE grade 4) adverse drug event (dermatologic, nephrologic, hematologic, neurologic, and/or endocrinologic) considered at least probable (by Leape and Bates criteria); * new non-invasive ventilation; * change of therapy (i.e., dose or agent) due to presumed treatment failure or probable adverse drug reaction (by Leape and Bates criteria); and * length of stay in hospital (amongst survivors)
Secondary	Proportion of patients that die (death)	Day 30	Mortality at day 30
Secondary	Proportion of patients with a need for new extracorporeal membrane oxygenation (ECMO),	Day 30	New initiation of extracorporeal membrane oxygenation during hospitalization following initiation of assigned PCP treatment strategy.
Secondary	Proportion of patients requiring new Invasive Mechanical Ventilation	Day 30	Initiation of invasive mechanical ventilation via endotracheal intubation during hospitalization following initiation of the assigned PCP treatment strategy.
Secondary	Proportion of patients with severe (CTCAE grade 4) adverse drug event	Day 30	Proportion of patients with occurence of severe (CTCAE grade 4) adverse drug event (dermatologic, nephrologic, hematologic, neurologic, and/or endocrinologic) considered at least probable (by Leape and Bates criteria).
Secondary	Proportion of patients with need for new non-invasive ventilation;	Day 30	initiation of non-invasive ventilation (including continuous positive airway pressure \[CPAP\] or bilevel positive airway pressure \[BiPAP\] during hospitalization following initiation of the assigned PCP treatment strategy.
Secondary	Proportion of patients requiring escalation or change of PCP -directed therapy	Day 30	Proportion of patients with escalation or change of PCP -directed therapy due to inadequate clinical response, disease progression, or treatment-limiting toxicity during the treatment or follow-up period.
Secondary	Median length of stay in hospital amongst survivors	Day 30	Length of hospital stay, measured in days from hospital admission to discharge among participants who survive to hospital discharge.
Other	Tertiary outcome measure of quality of life at day 30	Day 30	Quality of life (EQ-5D-5L) wherein a higher score indicates better quality of life.
Other	Tertiary outcome measure of all-cause mortality	Day 180	All-cause mortality, defined as death from any cause.
Other	Tertiary Outcome Measure of PCP recurrence	Day 180	Recurrence of pneumocystis pneumonia, defined as a new episode of clinically and/or microbiologically confirmed PCP after initial resolution.
Other	Tertiary Outcome measure of quality of life at day 180	Day 180	Quality of life assessed using a EQ-5D-5L questionnaire. High score indicates better quality of life.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07357103/registered

API reference For AI assistants